• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

斯塔加特病4型(ProgStar-4)研究进展:设计与基线特征(ProgStar-4报告第1号)

The Progression of the Stargardt Disease Type 4 (ProgStar-4) Study: Design and Baseline Characteristics (ProgStar-4 Report No. 1).

作者信息

Strauss Rupert W, Muñoz Beatriz, Ahmed Mohamed I, Bittencourt Millena, Schönbach Etienne M, Michaelides Michel, Birch David, Zrenner Eberhart, Ervin Ann-Margret, Charbel Issa Peter, Kong Jun, Wolfson Yulia, Shah Mahmood, Bagheri Saghar, West Sheila, Scholl Hendrik P N

机构信息

Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland, USA.

Moorfields Eye Hospital, NHS Foundation Trust, and UCL Institute of Ophthalmology, University College London, London, United Kingdom.

出版信息

Ophthalmic Res. 2018;60(3):185-194. doi: 10.1159/000491791. Epub 2018 Aug 15.

DOI:10.1159/000491791
PMID:30110705
Abstract

BACKGROUND/AIMS: To describe the design and baseline characteristics of patients enrolled in the multicenter, prospective natural history study of Stargardt disease type 4.

METHODS

Fifteen eligible patients aged 6 years and older at baseline, harboring disease-causing variants in the PROM1 gene, and with specified ocular lesions were enrolled. They were examined at baseline using a standard protocol, with 6 monthly follow-up visits for a 2-year period including best-corrected ETDRS visual acuity, spectral-domain optical coherence tomography, fundus autofluorescence (FAF), mesopic and scotopic microperimetry (MP). Areas of definitely decreased FAF (DDAF) and questionably decreased FAF were outlined and quantified on FAF images.

RESULTS

Amongst the 15 patients (29 eyes) that were enrolled at 5 centers in the USA and Europe, 10 eyes (34.5%) had areas of DDAF with an average lesion area of 3.2 ± 3.5 mm2 (range 0.36-10.39 mm2) at baseline. The mean retinal sensitivity of the posterior pole derived from mesopic MP was 8.8 ± 5.8 dB.

CONCLUSIONS

Data on disease progression in PROM1-related retinopathy from this study will contribute to the characterization of the natural history of disease and the exploration of the utility of several modalities to track progression and therefore to potentially be used in future interventional clinical trials.

摘要

背景/目的:描述参与4型斯塔加特病多中心前瞻性自然史研究的患者的设计和基线特征。

方法

纳入15例基线年龄6岁及以上、携带PROM1基因致病变异且有特定眼部病变的合格患者。他们在基线时采用标准方案进行检查,在2年期间每6个月随访一次,包括最佳矫正ETDRS视力、光谱域光学相干断层扫描、眼底自发荧光(FAF)、中视和暗视微视野检查(MP)。在FAF图像上勾勒并量化明确降低的FAF(DDAF)区域和可疑降低的FAF区域。

结果

在美国和欧洲的5个中心纳入的15例患者(29只眼)中,10只眼(34.5%)在基线时有DDAF区域,平均病变面积为3.2±3.5 mm2(范围0.36 - 10.39 mm2)。中视MP得出的后极平均视网膜敏感度为8.8±5.8 dB。

结论

本研究中关于PROM1相关视网膜病变疾病进展的数据将有助于疾病自然史的特征描述以及探索多种追踪进展的方法的效用,因此可能用于未来的干预性临床试验。

相似文献

1
The Progression of the Stargardt Disease Type 4 (ProgStar-4) Study: Design and Baseline Characteristics (ProgStar-4 Report No. 1).斯塔加特病4型(ProgStar-4)研究进展:设计与基线特征(ProgStar-4报告第1号)
Ophthalmic Res. 2018;60(3):185-194. doi: 10.1159/000491791. Epub 2018 Aug 15.
2
The Natural History of the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Studies: Design and Baseline Characteristics: ProgStar Report No. 1.《继发于斯塔加特病的萎缩自然史(ProgStar)研究:设计与基线特征》:ProgStar 报告第 1 号。
Ophthalmology. 2016 Apr;123(4):817-28. doi: 10.1016/j.ophtha.2015.12.009. Epub 2016 Jan 16.
3
Progression of Stargardt Disease as Determined by Fundus Autofluorescence in the Retrospective Progression of Stargardt Disease Study (ProgStar Report No. 9).在斯塔加特病回顾性进展研究(ProgStar报告第9号)中,通过眼底自发荧光确定的斯塔加特病进展情况。
JAMA Ophthalmol. 2017 Nov 1;135(11):1232-1241. doi: 10.1001/jamaophthalmol.2017.4152.
4
Incidence of Atrophic Lesions in Stargardt Disease in the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Study: Report No. 5.斯塔加特病萎缩进展研究(ProgStar)中斯塔加特病萎缩性病变的发生率:第5号报告
JAMA Ophthalmol. 2017 Jul 1;135(7):687-695. doi: 10.1001/jamaophthalmol.2017.1121.
5
Macular Sensitivity Measured With Microperimetry in Stargardt Disease in the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Study: Report No. 7.在斯塔加特病萎缩进展期斯塔加特病(ProgStar)研究中使用微视野计测量黄斑敏感性:第7号报告。
JAMA Ophthalmol. 2017 Jul 1;135(7):696-703. doi: 10.1001/jamaophthalmol.2017.1162.
6
Scotopic Microperimetric Assessment of Rod Function in Stargardt Disease (SMART) Study: Design and Baseline Characteristics (Report No. 1).斯塔加特病视杆细胞功能的暗视微视野评估(SMART)研究:设计与基线特征(报告第1号)
Ophthalmic Res. 2019;61(1):36-43. doi: 10.1159/000488711. Epub 2018 Jun 25.
7
Visual Acuity Change over 12 Months in the Prospective Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Study: ProgStar Report Number 6.12 个月内 Stargardt 病相关萎缩的前瞻性进展(ProgStar)研究中视力的变化:ProgStar 报告第 6 号。
Ophthalmology. 2017 Nov;124(11):1640-1651. doi: 10.1016/j.ophtha.2017.04.026. Epub 2017 May 23.
8
Progression of Stargardt Disease as Determined by Fundus Autofluorescence Over a 24-Month Period (ProgStar Report No. 17).Stargardt 病的进展情况通过 24 个月的眼底自发荧光(ProgStar 报告 17 号)确定。
Am J Ophthalmol. 2023 Jun;250:157-170. doi: 10.1016/j.ajo.2023.02.003. Epub 2023 Feb 9.
9
Longitudinal Microperimetric Changes of Macular Sensitivity in Stargardt Disease After 12 Months: ProgStar Report No. 13.《Stargardt 病患者黄斑敏感性在 12 个月后的纵向微视野计变化:ProgStar 报告 No.13》。
JAMA Ophthalmol. 2020 Jul 1;138(7):772-779. doi: 10.1001/jamaophthalmol.2020.1735.
10
Progression of Stargardt Disease as Determined by Fundus Autofluorescence Over a 12-Month Period: ProgStar Report No. 11.通过眼底自发荧光测定的Stargardt病在12个月期间的进展:ProgStar报告第11号。
JAMA Ophthalmol. 2019 Oct 1;137(10):1134-1145. doi: 10.1001/jamaophthalmol.2019.2885.

引用本文的文献

1
Prominin-1 Knockdown Causes RPE Degeneration in a Mouse Model.Prominin-1 敲低导致小鼠模型中的 RPE 退化。
Cells. 2024 Oct 24;13(21):1761. doi: 10.3390/cells13211761.
2
Genetic and clinical characteristics of PROM1-related retinal degeneration in Korean.韩国 PROM1 相关性视网膜变性的遗传和临床特征。
Sci Rep. 2023 Dec 11;13(1):21877. doi: 10.1038/s41598-023-49131-z.
3
Clinical Characteristics and Genetic Variants in Taiwanese Patients With PROM1-Related Inherited Retinal Disorders.台湾地区 PROM1 相关遗传性视网膜疾病患者的临床特征和基因突变
Invest Ophthalmol Vis Sci. 2023 Nov 1;64(14):25. doi: 10.1167/iovs.64.14.25.
4
Insights Into PROM1-Macular Disease Using Multimodal Imaging.多模态成像对 PROM1-黄斑疾病的研究进展。
Invest Ophthalmol Vis Sci. 2023 Apr 3;64(4):27. doi: 10.1167/iovs.64.4.27.
5
The role of multimodal imaging and vision function testing in -related retinopathies and their relevance to future therapeutic interventions.多模态成像和视觉功能测试在相关视网膜病变中的作用及其与未来治疗干预的相关性。
Ther Adv Ophthalmol. 2021 Dec 19;13:25158414211056384. doi: 10.1177/25158414211056384. eCollection 2021 Jan-Dec.
6
Deletion of in mice results in disrupted photoreceptor outer segment protein homeostasis.小鼠体内某物质的缺失会导致光感受器外段蛋白质稳态被破坏。 (注:原文中“Deletion of in mice”部分有缺失信息,这里是根据完整语义推测补充后的翻译)
Int J Ophthalmol. 2021 Sep 18;14(9):1334-1344. doi: 10.18240/ijo.2021.09.07. eCollection 2021.
7
Clinical Perspectives and Trends: Microperimetry as a Trial Endpoint in Retinal Disease.临床观点与趋势:微视野计在视网膜疾病中的试验终点应用。
Ophthalmologica. 2021;244(5):418-450. doi: 10.1159/000515148. Epub 2021 Feb 10.
8
Autosomal Recessive Bestrophinopathy: Clinical Features, Natural History, and Genetic Findings in Preparation for Clinical Trials.常染色体隐性 Bestrophinopathy:临床试验的临床特征、自然病史和遗传发现。
Ophthalmology. 2021 May;128(5):706-718. doi: 10.1016/j.ophtha.2020.10.006. Epub 2020 Oct 8.
9
Factors Influencing Retinal Pigment Epithelium-Atrophy Progression Rate in Stargardt Disease.影响斯塔加特病视网膜色素上皮萎缩进展速率的因素
Transl Vis Sci Technol. 2020 Jun 25;9(7):33. doi: 10.1167/tvst.9.7.33. eCollection 2020 Jun.
10
Clinical and Molecular Characterization of PROM1-Related Retinal Degeneration.PROM1 相关视网膜变性的临床和分子特征。
JAMA Netw Open. 2019 Jun 5;2(6):e195752. doi: 10.1001/jamanetworkopen.2019.5752.